The epicenter of the HIV epidemic is the Southern U.S., where 52% of all new U.S. HIV diagnoses occur and where 38% of the U.S. population lives. Nearly half of all deaths from HIV occur in the South (1). While bearing a heavy burden of HIV diagnoses and deaths, the Southern US lags behind...
A 67-year-old cisgender male with chronic HCV mono-infection was seen for treatment evaluation. He had no history of prior HCV treatment, and initial assessment revealed genotype 1a and a fibrosis score of F3/F4. Direct-acting antiviral (DAA) therapy using 12-weeks of sofosbuvir/velpat...
As an HIV service professional, you know that hopes for ending the HIV epidemic depend in large measure on maximizing the benefits of antiretroviral treatment (ART) by making sure clients receive treatment as soon as possible. Providing ART to people within seven days of new HIV diagnosis or re-enga...
Patients with chronic hepatitis C (CHC) should receive treatment with directly acting antivirals (DAAs) regardless of fibrosis stage. But does that mean that fibrosis is irrelevant? Absolutely not. Fibrosis remains a central concept in the care of patients with chronic liver disease, and patients wi...
With the end of the national and public health emergency declarations for COVID-19 on May 11, 2023, it's a good time to reflect on the journey we started nearly three years ago. The outbreak of a new and unknown disease brought many challenges, but for some, it was not their first pandemic experienc...
Impact of vaccination on incidence and severity of MPOX
Two recent studies from the CDC give insight into the impact of MPOX (formerly called monkeypox) vaccination in preventing infection, and on the severity of symptoms in those who became infected after vaccination.
The first examined the effect of...
Cicatelli Associates, Inc.'s TAP-in project created the national Imagine: Ending HIV. It’s Possible. (Imagine) campaign to inspire the HIV workforce to end the epidemic by reducing the number of new HIV infections by 90 percent by 2030. The Imagine campaign aims to improve staff’s leadership capacit...
The DoxyPEP Study evaluated the efficacy of doxycycline taken as post-exposure prophylaxis (PEP) on incidence of bacterial sexually transmitted infections (STIs), chlamydia (CT), gonorrhea (GC), and syphilis, in men who have sex with men (MSM) and transgender women (TGW).1 It was based on the earlie...
HIV care providers look to Integrating HIV Innovative Practices (IHIP) for evidence-based, evidence-informed, and emerging HIV care strategies they can adopt and integrate into their practice settings. With a library of over 75 user-friendly resources designed to address needs and gaps in services a...
The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. Lenacapavir is marketed in the United States as Sunlenca.
Lenacapavir blocks HIV-1’s assembly of its protein capsid and interferes with other steps in HIV rep...
A key study from 2022, the ANCHOR Study, proved that treatment of high-grade precursors to anal cancer can prevent the development of anal cancer in people with HIV (PWH).
Rates of anal cancer are substantially higher in PWH (both women and men) than in people without HIV. In a process analogous to...
Honoring our colleagues who dedicate additional time and resources to research beyond the scope of the AETC Program, we present the updated list of HIV-related peer-reviewed studies published in 2022 by AETC-affiliated researchers and faculty.
If you're aware of other HIV-related peer-reviewed publi...
(Cross-posted from TargetHIV)
To be resilient is to withstand and recover from difficult situations. For Black women with HIV, resilience is often expected but is rarely celebrated. In June 2022, staff from Grady Health System...
(Cross-posted from TargetHIV)
Each year, over 50,000 HIV care providers receive tailored HIV training from HRSA to better equip them to deliver HIV care to people with HIV with low incomes, according to a report from HRSA’s Ryan White HIV/AIDS Program (RWHAP).
Trainings reached a mix of nurses, docto...
Click on each date/tab below to reveal the schedule of AETC Program sessions and poster presentations planned for the 2022 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center will also be exhibiting and promoting AETC Program training materials,...
Imagine: Ending HIV. It’s Possible. is the name of a new, national campaign that launched this summer to encourage and energize the HIV workforce to achieve the national goal of ending the HIV epidemic.
The U.S. Department of Health and Human Services introduced the Ending the HIV Epidemic in the U.S...
Pharmacists have been identified by the CDC as key professionals in achieving one of the CDC’s goals of Ending the HIV Epidemic in the U.S. by preventing HIV infection. Below are some of the most common questions received at the AETC National Clinician Consultation Center (NCCC) from pharmacists abo...
Imagine living in a state with the second highest rate of chlamydia and the third highest rate of congenital syphilis infections in the United States (U.S.) in 2018. Our first thought was how can this be, and our second thought was what can we do to overcome this? When we looked at the 2019 U.S. Cen...
The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administer...
In December 2021, the U.S. Centers for Disease Control and Prevention issued thoroughly revised and updated PrEP guidelines. The guidelines include important new information on the use of oral PrEP (TDF/FTC and TAF/FTC) and recommendations on the use of injectable cabotegravir (CAB) as PrEP.
Key upda...
